Sanofi: quarterly EPS falls over 7% at CER

(CercleFinance.com) - Sanofi reports business EPS of E1.
78 for Q1 2024, down 17.6% as reported and down 7.4% at constant exchange rates, notably reflecting an 11.8% rise in R&D expenditure.

At nearly E10.5bn, sales rose by 2.4% (+6.7% at CER), with growth driven by the continued strong performance of Dupixent and new launches, management said.

The French healthcare group expects its 2024 business EPS to fall in the low single-digit range at CER, taking into account the expected increase in the tax rate, barring unforeseen major adverse events.


Copyright (c) 2024 CercleFinance.com. All rights reserved.